Table 1 Representative potential therapeutic drugs and their targets in various types of cancers that have been assessed by xenograft models [133]
From: Current status and perspectives of patient-derived xenograft models in cancer research
Drug or combination | Target | Cancer type | Mouse | References |
|---|---|---|---|---|
DEL-22379 | Erk | Colorectal cancer | NOD/SCID | [134] |
CSL362 | CD123 | AML | NSG | [135] |
Bicalutamide | Androgen | Prostate cancer | SCID | [72] |
FP3 | VEGF | Colon cancer | Nude | [71] |
Pyruvinium pamoate | Glutathione | Lymphoma | NOG | [116] |
Ponatinib, dovitinib, and BGJ398 | FGFR | Cholangiocarcinoma | NSG | Â |
Luteolin | cMet | Gastric cancer | Nude | [95] |
BKM120 | PI3K inhibitor | Pancreatic adenocarcinoma | NSG | [52] |
Erlotinib and gefitinib | EGFR | Chordomas | Nude | [86] |
Salmonella A1-R | - | Melanoma | Nude | [104] |
Salmonella A1-R and doxorubicin | - | Sarcoma | Nude | [103] |
Trastuzumab | Her2 | Esophageal squamous cell carcinoma | Nude and SCID | [99] |
Trastuzumab/cetuximab | Her2/EGFR | Gastric cancer | Nude | [98] |
Cetuximab/bevacizumab | EGFR/VEGF | Colon cancer | Nude | [136] |
Cetuximab | EGFR | Lung Adenocarcinoma | NOD/SCID | [87] |
AZD5363 | AKT | Gastric cancer | Nude | [88] |
Brequinar | Dihydroorotate dehydrogenase | AML | SCID | [137] |
GSK2879552 | LSD1, lysine demethylase 1 | Small cell lung cancer | Nude | [138] |
Anti-CD47 antibody | CD47 | Non-Hodgkin lymphoma | NSG | [114] |
CHZ868 | JAK2 | B-ALL | NSG | [139] |
HA15 | Bip | Melanoma | nude | [140] |
UNC0379 | SETD8 | Neuroblastoma | Nude | [141] |
PARP inhibitors and β-lapachone | DNA repair | Pancreatic cancer and NSCLC | NOD/SCID | [142] |
MCB-613 | Steroid Receptor Coactivator | Breast cancer (MCF-7) | Nude | [143] |
P5091 | USP7 | Multiple myeloma | SCID | [144] |
MLN8237 and ABT-199 | Aurora kinase and BCL-2 | Neuroblastoma | SCID | [111] |
TH287 and TH588 | MTH1 | Melanoma | NOG | [93] |
Agonists | HIF-2 | Renal cell carcinoma | Nude | [145] |
SSR128129E (SSR) | FGFR | Lewis lung carcinoma And breast cancer | Nude | [146] |
CH5424802 | ALK | NSCLC | SCID or nude | [147] |
ON01910 | Plk1 | Liver, breast, and pancreatic cancers | Nude | [148] |
Shepherdin | ATP pocket of Hsp90 | Prostate cancer | SCID and beige | [149] |
PD0325901 | MEK | BRAF mutant cancer | Nude | [150] |
Monoclonal antibody | S1P | Multiple cancers | Nude | [151] |
NSC23766 | Rac | P210-BCR-ABL positive CML | NOD/SCID | [152] |
Argyrin A | Proteasome | Colon cancer | Nude | [153] |
Syk inhibitors | Syk | AML | NOG | [154] |
Polyphenylureas | XIAP, an apoptosis suppressor | Prostate and colon cancers | Nude | [155] |
RD162 and MDV3100 | Androgen | Advanced prostate cancer | SCID | [156] |
EPI-001 | Androgen receptor NTD domain | Castrate-recurrent prostate cancer | NOD/SCID | [157] |
piperlongumine | Stress response to ROS | Multiple cancers | nude | [158] |
CFI-400945, inhibitor | PLK4 | Multiple cancers | NSG and SCID | [159] |
BDA-366 | Bcl2 BH4 domain | Lung cancer | Nude | [160] |
CCT196969, CCT241161 | pan-RAF and SFKs | Multiple cancers | Nude | [161] |
SR9243, LXR inverse agonist | LXR | Multiple cancers | Nude | [162] |
SHP099 | SHP2 | RTK-driven cancer | Nude | [163] |
Antibody | RSPO3 | Colorectal cancer | Nude | [164] |
CB-5083 | AAA ATPase p97 | Multiple myeloma and solid tumors | Nude and SCID-Beige | [165] |
BI-505 | ICAM-1 | B cell cancer and MM | SCID | [166] |
MLN4924 | NEDD8-Activating Enzyme | Multiple cancers | SCID | [167] |
Selinexor (KPT-330) | XPO1 | AML | NSG | [168] |
Matrix metalloproteinase inhibitor prinomastat (AG3340) | Matrix metalloproteinase | Pancreatic ductal adenocarcinoma | SCID | [169] |